These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 34531254)

  • 1. An
    Lin S; Larrue C; Scheidegger NK; Seong BKA; Dharia NV; Kuljanin M; Wechsler CS; Kugener G; Robichaud AL; Conway AS; Mashaka T; Mouche S; Adane B; Ryan JA; Mancias JD; Younger ST; Piccioni F; Lee LH; Wunderlich M; Letai A; Tamburini J; Stegmaier K
    Cancer Discov; 2022 Feb; 12(2):432-449. PubMed ID: 34531254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.
    Chen X; Glytsou C; Zhou H; Narang S; Reyna DE; Lopez A; Sakellaropoulos T; Gong Y; Kloetgen A; Yap YS; Wang E; Gavathiotis E; Tsirigos A; Tibes R; Aifantis I
    Cancer Discov; 2019 Jul; 9(7):890-909. PubMed ID: 31048321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Exploration of novel therapeutic targets in acute myeloid leukemia via genome-wide CRISPR screening].
    Yamauchi T
    Rinsho Ketsueki; 2019; 60(7):810-817. PubMed ID: 31391371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting leukemia-specific dependence on the de novo purine synthesis pathway.
    Yamauchi T; Miyawaki K; Semba Y; Takahashi M; Izumi Y; Nogami J; Nakao F; Sugio T; Sasaki K; Pinello L; Bauer DE; Bamba T; Akashi K; Maeda T
    Leukemia; 2022 Feb; 36(2):383-393. PubMed ID: 34344987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SLC5A3-Dependent Myo-inositol Auxotrophy in Acute Myeloid Leukemia.
    Wei Y; Huang YH; Skopelitis DS; Iyer SV; Costa ASH; Yang Z; Kramer M; Adelman ER; Klingbeil O; Demerdash OE; Polyanskaya SA; Chang K; Goodwin S; Hodges E; McCombie WR; Figueroa ME; Vakoc CR
    Cancer Discov; 2022 Feb; 12(2):450-467. PubMed ID: 34531253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-scale drop-out screens to identify cancer cell vulnerabilities in AML.
    Basheer FT; Vassiliou GS
    Curr Opin Genet Dev; 2019 Feb; 54():83-87. PubMed ID: 31063922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.
    Nechiporuk T; Kurtz SE; Nikolova O; Liu T; Jones CL; D'Alessandro A; Culp-Hill R; d'Almeida A; Joshi SK; Rosenberg M; Tognon CE; Danilov AV; Druker BJ; Chang BH; McWeeney SK; Tyner JW
    Cancer Discov; 2019 Jul; 9(7):910-925. PubMed ID: 31048320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target.
    Vujovic A; de Rooij L; Chahi AK; Chen HT; Yee BA; Loganathan SK; Liu L; Chan DCH; Tajik A; Tsao E; Moreira S; Joshi P; Xu J; Wong N; Balde Z; Jahangiri S; Zandi S; Aigner S; Dick JE; Minden MD; Schramek D; Yeo GW; Hope KJ
    Blood Cancer Discov; 2023 May; 4(3):180-207. PubMed ID: 36763002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML.
    Nguyen NHK; Rafiee R; Tagmount A; Sobh A; Loguinov A; de Jesus Sosa AK; Elsayed AH; Gbadamosi M; Seligson N; Cogle CR; Rubnitz J; Ribeiro R; Downing J; Cao X; Pounds SB; Vulpe CD; Lamba JK
    Blood Adv; 2023 May; 7(9):1769-1783. PubMed ID: 36111891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.
    Tzelepis K; Koike-Yusa H; De Braekeleer E; Li Y; Metzakopian E; Dovey OM; Mupo A; Grinkevich V; Li M; Mazan M; Gozdecka M; Ohnishi S; Cooper J; Patel M; McKerrell T; Chen B; Domingues AF; Gallipoli P; Teichmann S; Ponstingl H; McDermott U; Saez-Rodriguez J; Huntly BJP; Iorio F; Pina C; Vassiliou GS; Yusa K
    Cell Rep; 2016 Oct; 17(4):1193-1205. PubMed ID: 27760321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia.
    Brinton LT; Zhang P; Williams K; Canfield D; Orwick S; Sher S; Wasmuth R; Beaver L; Cempre C; Skinner J; Cannon M; Govande M; Harrington B; Lehman A; Byrd JC; Lapalombella R; Blachly JS
    J Hematol Oncol; 2020 Oct; 13(1):139. PubMed ID: 33076970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
    Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
    Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.
    Eide CA; Kurtz SE; Kaempf A; Long N; Agarwal A; Tognon CE; Mori M; Druker BJ; Chang BH; Danilov AV; Tyner JW
    Leukemia; 2020 Sep; 34(9):2342-2353. PubMed ID: 32094466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets.
    Carlet M; Völse K; Vergalli J; Becker M; Herold T; Arner A; Senft D; Jurinovic V; Liu WH; Gao Y; Dill V; Fehse B; Baldus CD; Bastian L; Lenk L; Schewe DM; Bagnoli JW; Vick B; Schmid JP; Wilhelm A; Marschalek R; Jost PJ; Miething C; Riecken K; Schmidt-Supprian M; Binder V; Jeremias I
    Nat Commun; 2021 Sep; 12(1):5655. PubMed ID: 34580292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large-Scale In Vitro and In Vivo CRISPR-Cas9 Knockout Screens Identify a 16-Gene Fitness Score for Improved Risk Assessment in Acute Myeloid Leukemia.
    Jin P; Jin Q; Wang X; Zhao M; Dong F; Jiang G; Li Z; Shen J; Zhang W; Wu S; Li R; Zhang Y; Li X; Li J
    Clin Cancer Res; 2022 Sep; 28(18):4033-4044. PubMed ID: 35877119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis targeted therapies in acute myeloid leukemia: an update.
    Ball S; Borthakur G
    Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
    [No Abstract]   [Full Text] [Related]  

  • 17. Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage.
    Bi S; Chen K; Feng L; Fu G; Yang Q; Deng M; Zhao H; Li Z; Yu L; Fang Z; Xu B
    Eur J Pharmacol; 2019 Jul; 855():252-261. PubMed ID: 31085238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia.
    Elgamal OA; Mehmood A; Jeon JY; Carmichael B; Lehman A; Orwick SJ; Truxall J; Goettl VM; Wasmuth R; Tran M; Mitchell S; Lapalombella R; Eathiraj S; Schwartz B; Stegmaier K; Baker SD; Hertlein E; Byrd JC
    J Hematol Oncol; 2020 Jan; 13(1):8. PubMed ID: 31992353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine.
    Lam SS; He AB; Leung AY
    Blood Rev; 2017 Nov; 31(6):418-425. PubMed ID: 28797519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains.
    Shi J; Wang E; Milazzo JP; Wang Z; Kinney JB; Vakoc CR
    Nat Biotechnol; 2015 Jun; 33(6):661-7. PubMed ID: 25961408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.